Search Results

You are looking at 1 - 2 of 2 items for :

  • "norditropin" x
  • Paediatric Endocrinology x
Clear All
Alexander A L Jorge Unidade de Endocrinologia-Genetica, LIM/25, Disciplina de Endocrinologia da Faculdade de Medicina da Universidade de Sao Paulo (FMUSP), Sao Paulo, Brazil

Search for other papers by Alexander A L Jorge in
Google Scholar
PubMed
Close
,
Thomas Edouard Endocrine, Bone Diseases, and Genetics Unit, Children’s Hospital, Toulouse University Hospital, RESTORE INSERM UMR1301, Toulouse, France

Search for other papers by Thomas Edouard in
Google Scholar
PubMed
Close
,
Mohamad Maghnie Department of Pediatrics, IRCCS Istituto Giannina Gaslini, Genova, Italy
Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova, Genova, Italy

Search for other papers by Mohamad Maghnie in
Google Scholar
PubMed
Close
,
Alberto Pietropoli Novo Nordisk Health Care AG, Global Medical Affairs Biopharm, Zürich, Switzerland

Search for other papers by Alberto Pietropoli in
Google Scholar
PubMed
Close
,
Nicky Kelepouris Novo Nordisk Inc., Clinical, Medical and Regulatory Biopharm-RED, Plainsboro, New Jersey, USA

Search for other papers by Nicky Kelepouris in
Google Scholar
PubMed
Close
,
Alicia Romano Department of Pediatrics, New York Medical College, Valhalla, New York, USA

Search for other papers by Alicia Romano in
Google Scholar
PubMed
Close
,
Martin Zenker Institute of Human Genetics & Department of Pediatrics, University Hospital, Otto-von-Guericke University Magdeburg, Magdeburg, Germany

Search for other papers by Martin Zenker in
Google Scholar
PubMed
Close
, and
Reiko Horikawa Department of Endocrine and Metabolism, National Center for Child Health and Development, Tokyo, Japan

Search for other papers by Reiko Horikawa in
Google Scholar
PubMed
Close

mutation ( 9 , 18 ). Norditropin® (somatropin; Novo Nordisk A/S) is a recombinant human GH (rhGH) that is used as replacement therapy in patients with GHD or to treat a number of other conditions characterized by insufficient growth (US Food and Drug

Open access
Régis Coutant Department of Pediatric Endocrinology and Diabetology, Reference Center for Rare Pituiatry Diseases, University Hospital of Angers, Angers, France

Search for other papers by Régis Coutant in
Google Scholar
PubMed
Close
,
Maithé Tauber Reference Center for the Prader-Willi syndrome and other rare obesities with feeding disorders (PRADORT), Children Hospital, CHU Toulouse, Toulouse, France
Pediatric team of the Clinical Investigation Center 9302/INSERM, Hospital of Children, Toulouse, France
Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), INSERM UMR1291 - CNRS UMR5051 - Université Toulouse III, Toulouse, France

Search for other papers by Maithé Tauber in
Google Scholar
PubMed
Close
,
Béatrice Demaret GRANDIR - French Growth Disorders Association, Asnières-sur-Seine, France

Search for other papers by Béatrice Demaret in
Google Scholar
PubMed
Close
,
Robin Henocque Pfizer France, Paris France

Search for other papers by Robin Henocque in
Google Scholar
PubMed
Close
,
Yves Brault Pfizer France, Paris France

Search for other papers by Yves Brault in
Google Scholar
PubMed
Close
,
François Montestruc eXYSTAT, Malakoff, France

Search for other papers by François Montestruc in
Google Scholar
PubMed
Close
,
Olivier Chassany Health Economics Clinical Trial Unit (URC-ECO), Hospital of Hotel-Dieu, AP-HP, Paris, France
Patient-Reported Outcomes Unit (PROQOL), UMR 1123, University Paris Cité, INSERM, Paris, France

Search for other papers by Olivier Chassany in
Google Scholar
PubMed
Close
,
Michel Polak Hôpital Universitaire Necker Enfants Malades, Pediatric Endocrinology, Gynecology and Diabetology, Imagine Institute, INSERM U1163, Cochin Institute, INSERM U1016, Centre de référence des pathologies endocriniennes rares de la croissance et du développement, Université de Paris Cité, Paris, France

Search for other papers by Michel Polak in
Google Scholar
PubMed
Close
, and
the QOLITHOR Study Group
Search for other papers by the QOLITHOR Study Group in
Google Scholar
PubMed
Close
the QOLITHOR Study Group

(%)  Norditropin FlexPro® 32 (44.4%) 41 (36.6%) 26 (28.6%) 99 (36.0%) 20 (45.5%) 26 (37.7%) 19 (35.8%) 65 (39.2%)  Saizen® 22 (30.6%) 19 (17.0%) 20 (22.0%) 61 (22.2%) 14 (31.8%) 15 (21.7%) 11 (20.8%) 40 (24.1%)  Omnitrope

Open access